Émilien Delmont

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 269 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +11

Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy

Émilien Delmont, Constance Manso, Luís Querol et al. · Brain · 2017 · 234 citations · Full text

Life Sciences, Immunology, Neurology +17

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Multifocal motor neuropathy with and without conduction block

Émilien Delmont, Jean‐Philippe Azulay, Roch Giorgi et al. · Neurology · 2006 · 118 citations

Medicine, Neurology, Neuroscience +13